CO108 Subgroup Analysis of Quality of Life and Treatment Satisfaction By Disease Duration and Use of PRIOR Treatment: Pooled Results from Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo

Abstract

Vitiligo is a chronic autoimmune skin disease that impacts patient quality of life (QoL). Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream demonstrated clinically meaningful repigmentation and was generally well tolerated in the 52-week TRuE-V1/TRuE-V2 randomized phase 3 vitiligo studies. Pooled interim subgroup analyses of patient-reported outcomes are reported based on disease duration and use of prior treatment.